Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade , Belgrade , Serbia.
University Clinical Hospital Center Bezanijska Kosa, School of Medicine, University of Belgrade , Belgrade , Serbia.
Curr Med Res Opin. 2019 Nov;35(11):1873-1883. doi: 10.1080/03007995.2019.1647021. Epub 2019 Aug 26.
Cardiovascular disease (CVD) drugs have been frequently implicated in adverse drug reaction (ADR)-related hospitalizations. Drug-drug interactions (DDIs) are common preventable cause of ADRs, but the impact of DDIs in the CVD population has not been investigated. Hence, the primary aim of the study was to identify DDIs associated with ADRs in CVD patients at hospital admission. The second aim was to develop a simple tool to identify high-risk patients for DDI-related adverse events. An observational study was conducted on the Cardiology Ward of University Clinical Hospital Center. Data were obtained from medical charts. A clinical panel identified DDIs implicated in ADRs, using LexiInteract database and Drug Interaction Probability Scale. Statistics were performed using PASW 22 (SPSS Inc.). DDIs contributed to hospital admission with a total prevalence of 9.69%. DDI-related ADRs affected mainly cardiac function (heart rate or rhythm, 41.07%); bleeding and effect on blood pressure were equally distributed (17.86%). Non-cardiovascular ADRs were found in 23.21% of DDIs. After admission, 73% of the identified DDIs led to changes in prescription. Prediction ability of calculated DDI adverse event probability scores was rated as good (AUC = 0.80, < .001). CVD patients are highly exposed to adverse DDIs; about one in ten patients hospitalized with CVD might have a DDI contributing to the hospitalization. Given the high prevalence of CVD, DDI-related harm might be a significant burden worldwide. Identification of patients with high DDI adverse event risk might ease the recognition of DDI-related harm and improve the use of electronic databases in clinical practice.
心血管疾病 (CVD) 药物经常与药物不良反应 (ADR) 相关的住院有关。药物-药物相互作用 (DDI) 是常见的可预防的 ADR 原因,但 CVD 人群中 DDI 的影响尚未得到研究。因此,研究的主要目的是确定与 CVD 患者入院时 ADR 相关的 DDI。第二个目的是开发一种简单的工具来识别因 DDI 而发生不良事件的高危患者。一项观察性研究在大学临床中心心脏病科进行。数据来自病历。临床小组使用 LexiInteract 数据库和药物相互作用可能性量表识别与 ADR 相关的 DDI。使用 PASW 22(SPSS Inc.)进行统计分析。DDI 导致住院的总患病率为 9.69%。DDI 相关的 ADR 主要影响心脏功能(心率或节律,41.07%);出血和血压影响的发生率相等(17.86%)。非心血管 ADR 在 23.21%的 DDI 中发现。入院后,73%的识别 DDI 导致处方改变。计算的 DDI 不良事件概率评分的预测能力被评为良好(AUC = 0.80,< 0.001)。CVD 患者极易受到不良 DDI 的影响;每 10 名因 CVD 住院的患者中,可能有 1 名患者的住院与 DDI 有关。鉴于 CVD 的高患病率,DDI 相关的危害可能在全球范围内造成重大负担。识别具有高 DDI 不良事件风险的患者可能有助于识别 DDI 相关的危害,并改善电子数据库在临床实践中的使用。